Marksans Pharma Q1FY27: Revenue up 35.6% to ₹841 Cr, PAT surges 173.9% to ₹159 Cr
Marksans Pharma reported Q1FY27 revenue of ₹841 crore, a 35.6% YoY increase. PAT surged 173.9% to ₹159 crore, and EBITDA grew 112.8% to ₹213 crore. The UK & Europe region showed strong growth, up 74.7% YoY. The company's cash balance crossed ₹1,058 crore. Acquisitions of QliniQ and ABCnow were completed.
The substantial increase in revenue and profit, coupled with margin expansion and strategic acquisitions, indicates a significant positive impact on the company's financial performance and future growth prospects.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with significant margin expansion. The management commentary is optimistic, highlighting key achievements and future growth strategies, supported by successful acquisitions and a strong balance sheet.
Marksans Pharma Limited announced its financial results for the first quarter of FY27 (Q1FY27), reporting a significant year-on-year (YoY) growth in revenue and profit. The company's revenue increased by 35.6% to ₹841 crore compared to ₹620 crore in Q1FY26. The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw a substantial jump of 112.8% to ₹213 crore from ₹100 crore in the same period last year, with the EBITDA margin expanding by 919 basis points to 25.3% from 16.1%. Profit After Tax (PAT) surged by 173.9% to ₹159 crore, up from ₹58 crore in Q1FY26, and the Net Profit Margin improved to 18.4% from 9.3%.
The management highlighted strong performance across geographies, with the UK & Europe region delivering its highest-ever quarterly revenue of ₹356 crore, a YoY growth of 74.7%. Europe is identified as a significant growth engine following the acquisition of QliniQ, which contributed ₹44 crore in the quarter. The company also crossed ₹1,000 crore in cash balance for the first time, closing the quarter at ₹1,058 crore. Looking ahead, the company plans to scale its businesses, accelerate new launches, and further strengthen its European platform.
Geographically, US & North America contributed ₹377 crore (15.1% YoY growth), Australia & New Zealand ₹88 crore (53.7% YoY growth), and Rest of World ₹20 crore (-36.8% YoY growth). The company completed the acquisitions of QliniQ B.V. in the Netherlands and ABCnow GmbH in Germany. Strategic progress in the quarter included establishing a European front-end presence and strengthening the balance sheet to fund growth.
What to do with a filing like this
Marksans Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Marksans Pharma Limited. Read the original for the full detail.